Drs Arnold, Cohen, and Magnuson review the published cost-effectiveness analyses of oral antiplatelet therapies for various clinical settings. This information is of increasing importance, given the enormous health-care expenditure worldwide, the advent of novel oral antiplatelet drugs, and the availability in many countries of generic clopidogrel, which is cheaper than the branded version and likely to improve its cost-effectiveness compared with alternative medications.
- Suzanne V. Arnold
- David J. Cohen
- Elizabeth A. Magnuson
